Group 1 - The core viewpoint of the news is that Sai Sheng Pharmaceutical (300485.SZ) has reported an increase in institutional and foreign investment holdings as of August 21, 2025, indicating growing interest from investors [1][2] - As of the report date, a total of 6 institutional investors hold shares in Sai Sheng Pharmaceutical, with a combined holding of 8.8971 million shares, representing 1.85% of the total share capital, which is an increase of 0.86 percentage points from the previous quarter [1] - The public funds disclosed during this period include two new funds: GF Technology Innovation Mixed A and Huatai-PineBridge CSI 2000 ETF, while two funds were no longer disclosed: JY Shun'an Yuanqi Flexible Allocation Mixed and Wan Jia Medical Quantitative Stock Selection Mixed Initiation A [1] Group 2 - In terms of foreign investment, one foreign fund, Morgan Stanley & Co. International PLC, increased its holdings by 0.16% compared to the previous quarter [2] - Two new foreign institutions disclosed during this period are UBS AG and Barclays Bank PLC, while Hong Kong Central Clearing Limited and Goldman Sachs LLC were no longer disclosed [2]

Core Viewpoint - The article provides a ranking of open-end mutual funds based on their net asset value growth as of August 6, 2025, highlighting the top and bottom performers in the market [2][4][6]. Group 1: Top Performing Funds - The top 10 funds with the highest net value growth include: 1. Zhonghai Charm Yangtze River Delta Mixed Fund (3.1350) 2. Hengyue Smart Technology Mixed C Fund (1.1892) 3. Hengyue Smart Technology Mixed A Fund (1.1996) 4. Minsheng Jianyin Frontier Technology Mixed Fund (1.0201) 5. Tongtai Competitive Advantage Mixed A Fund (1.1032) 6. Tongtai Competitive Advantage Mixed C Fund (1.0802) 7. Furong Fuxin Mixed C Fund (2.1194) 8. Furong Fuxin Mixed A Fund (2.1560) 9. Hongyi Yuanfang Selected Mixed C Fund (1.1215) 10. Hongyi Yuanfang Selected Mixed A Fund (1.1231) [2][4]. Group 2: Bottom Performing Funds - The bottom 10 funds with the lowest net value growth include: 1. Guotai Innovation Medical Mixed Initiation C Fund (1.1799) 2. Guotai Innovation Medical Mixed Initiation A Fund (1.1901) 3. Wanjia Pharmaceutical Quantitative Stock Selection Mixed Initiation C Fund (1.2070) 4. Wanjia Pharmaceutical Quantitative Stock Selection Mixed Initiation A Fund (1.2165) 5. Morgan Stanley Youyue Anhe Mixed C Fund (0.6632) 6. Morgan Stanley Youyue Anhe Mixed A Fund (0.6727) 7. Hongde Medical Innovation Mixed Initiation A Fund (1.0426) 8. Hongde Medical Innovation Mixed Initiation C Fund (1.0274) 9. Guotai Growth Enterprise Board Medical Health ETF (1.2310) 10. Tianhong Medical Innovation A Fund (1.0690) [4][6]. Group 3: Market Overview - The Shanghai Composite Index showed a slight upward trend, with a trading volume of 1.75 trillion, and the number of advancing stocks was 3,357 compared to 1,817 declining stocks [6]. - Leading sectors included shipbuilding and general machinery, both rising over 3%, while the tourism sector experienced declines [6].